Skip to main content
. 2021 Jan 18;21(3):211. doi: 10.3892/ol.2021.12472

Figure 5.

Figure 5.

MCM3AP-AS1/miR-138 increases gastric cancer cell resistance to CDDP via regulating FOXC1. (A) FOXC1 expression in AGS/CDDP cells transfected with pcDNA3.1 and pcDNA3.1-FOXC1. (B) FOXC1 expression was assessed in AGS/CDDP cells transfected with shNC, shMCM3AP-AS1#1 and shMCM3AP-AS1#1+FOXC1 groups by RT-qPCR and western blot assays. (C) FOXC1 expression was assessed in AGS/CDDP cells transfected with NC mimics, miR-138 mimics and miR-138 mimics+FOXC1 groups by RT-qPCR and western blot assays. (D) Migratory (magnification, ×200) and (E) invasive abilities (magnification, ×200) of AGS/CDDP cells were detected in different groups by wound healing and Transwell assays, respectively. (F) Cell viability of AGS/CDDP cells was measured in shNC, shMCM3AP-AS1#1 and shMCM3AP-AS1#1+FOXC1 groups, as well as NC, mimics, miR-138 mimics and miR-138 mimics+FOXC1 groups by Cell Counting Kit-8 assay. (G) The IC50 of AGS/CDDP cells was tested in shNC, shMCM3AP-AS1#1 and shMCM3AP-AS1#1+FOXC1 groups, as well as NC, mimics, miR-138 mimics and miR-138 mimics+FOXC1 groups by drug-sensitivity assay. *P<0.05. miR, microRNA; MCM3AP-AS1, MCM3AP antisense RNA 1; CDDP, cisplatin; RT-qPCR, reverse transcription-quantitative PCR; sh, short hairpin RNA; NC, negative control; OD, optical density.